Ċ		,		7/25/1	7
•	4.	CERTIFICATE OF MAILING			Ho
	I hereby certify that this correspondence is being deposited Commissioner for Patents, Washington, D.C. 20231.	with the United States Postal Service	as first class mail in an envelop	e addressed to: Assistant	r
	Typed or Printed Name Donna Macedo		-		
	Signature	leado	Date 3/12	102	
	DECE				
	PRELIMINARY AMENDMENT	Attorney Docket Confirmation No.	CLON037CON 3391	RECE	VED
2 1	P	First Named Inventor	Репту	APR 0 3	2002
	Address to:	Application Number	09/839,696		1
	Commissioner for Patents	Filing Date	April 19, 2001	TECH CENTER:	000/00
	Washington, D.C. 20231	Group Art Unit	1653		000/2900
	(بنب	Examiner Name	Unassigned		1
_	ARKONE	Title	Novel Method for P	urification of	1
OP.	BHL.			Recombinant Proteins	

Sir:

Prior to examination of the application on the merits, please enter the following amendments:

AMENDMENTS

In the claims:

Please add the following new claims:

- --24. (New) An immobilized metal ion affinity chromatography complex comprising:
 - (a) an aspartate metal chelating ligand; and
 - (b) a transition metal ion complexed to said asparate metal chelating ligand.
- 25. (New) The immobilized metal ion affinity chromatography complex according to Claim 24, wherein said aspartate ligand is a tetradentate ligand.

1/2004 TJOHNSO4 00000004 500015 09039696

- FC: 120126. (New) The immobilized metal ion affinity chromatography complex according to Claim 24, wherein said transition metal is complexed to said ligand in octahedral geometry.
 - 27. (New) The immobilized metal ion affinity chromatography complex according to Claim 24, wherein said transition metal ion is selected from the group consisting of Fe²⁺, Co²⁺, Ni²⁺, Cu²⁺ and Zn²⁺.

04/01/2002 NBERHE 00000040 500815 0983969

01 FC:103 162.00 CH

Atty Dkt. No.: CLON037CON USSN: 09/839,696

36. (New) The method according to Claim 31, wherein said complex offers two available valencies.

37. (New) The immobilized metal ion affinity chromatography complex according to Claim 36, wherein said two available valencies form strong, reversible complexes with adjacent histidine residues on the surface of said protein. —

REMARKS UNDER 37 CFR § 1.111

Newly presented Claims 24-37 find support throughout the specification and originally pending claims. As such, there entry and examination by the Examiner is respectfully requested.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number CLON37DIV.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date: 3. 12.02

By: Bret E. Field

Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP 200 Middlefield Road, Suite 200 Menlo Park, CA 94025

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\CLON\037CON\Preliminary Amendment.doc